TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19583072
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of NSAID and adjuvant treatment
Study: 11444999
Drug: Methionine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine (100 mg/Kg) plus vitamin C (2 g orally)
Study: 11444999
Drug: Methionine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine (100 mg/Kg) plus placebo tablets
Study: 11444999
Drug: Placebo drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drink plus placebo tablets
Study: 7970045
Drug: 6% neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% neostigmine (1 puff = 5.4 mg), 2 puffs per nostril, repeated every 4 hours up to 6 puffs/day for 4 days or until canalization of feces and gas was achieved.
Study: 19890639
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (low-dose)
Study: 19890639
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (low-dose)
Study: 12925515
Drug: Biased-coin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biased-coin treatment allocation rules
Study: 8856091
Drug: Alternating monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Alternating monthly cycles of IFN-alpha and chemotherapy (group II)
Study: 1622852
Drug: ARGIMESNA p.o.,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARGIMESNA p.o., 20% of IFO dose every 2 h x 4
Study: 1622852
Drug: MESNA p.o.,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MESNA p.o., 40% of IFO dose every 4 h x 2
Study: 31342780
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (language treatment 20 minutes a day, six days/week, for five weeks)
Study: 27624513
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care intervention model with cognitive-behavioral therapy, care management, and psychopharmacological consultation.
Study: 26842203
Drug: TMX/GOS (Tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMX/GOS (Tamoxifen 20 mg/day for 5 years plus Goserelin 3.6 mg injection per month for 2 years)
Study: 26842203
Drug: TMX (Tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMX (Tamoxifen 20 mg/day for 5 years)
Study: 22677304
Drug: Topical preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical preparations (0.1% tretinoin, 0.1% adapalene, 5% dapsone, 1% clindamycin, benzoyl peroxide with adapalene or clindamycin, clindamycin-tretinoin combination)
Study: 22677304
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide preparations (2 for 2.5%, 3 for 5.0%)
Study: 22677304
Drug: Vehicle (placebo)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (placebo) for benzoyl peroxide preparations
Study: 22677304
Drug: Overall vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall vehicle contribution toward drug effect
Study: 20406218
Drug: PF-00821385 (0.5-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-00821385 (0.5-120 mg kg(‐1))
Study: 20406218
Drug: PF-00821385 (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-00821385 (administered to 24 volunteers)
Study: 16278521
Drug: Amlodipine besylate/benazepril
Normalized name: amlodipine besylate/benazepril 5 mg-10 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine besylate/benazepril HCl 5/20 mg combination therapy
Study: 16687966
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate 5 mg
Study: 16278521
Drug: Benazepril HCl
Normalized name: benazepril HCl
DrugBank: Benazepril (DB00542)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benazepril HCl 20 mg
Study: 10442509
Drug: PGE1 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE1 (60 microg given daily i.v. over 2 hours in 250 ml saline, n = 12)
Study: 10442509
Drug: Placebo (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (250 ml saline, n = 12)
Study: 2349372
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg orally, 14 h before)
Study: 28762896
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate (5 mg/day)
Study: 26923613
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/day immediately (Group A)
Study: 26923613
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/day 7 days after enrollment (Group B)
Study: 26923613
Drug: No fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No fluoxetine (Group C)
Study: 22179140
Drug: DXA scans
Approvals — FDA: no, EMA: no, PMDA: no
Description: DXA scans after daily activities
Study: 20004725
Drug: Alcohol intoxication
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol intoxication (target blood alcohol level of 50 mg%)
Study: 17285425
Drug: Fentanyl (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (10 microg/kg at induction and 5 microg/kg/h infusion for maintenance)
Study: 17285425
Drug: Remifentanil (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (3 microg/kg at induction and 1 microg/kg/min infusion for maintenance)
Study: 16540790
Drug: Zinc (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (20 mg orally, once daily for 14 days) with ORS
Study: 12889593
Drug: NICHD Maternal
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NICHD Maternal Fetal Medicine Units Network trials (specific interventions not detailed)
Study: 6657514
Drug: Vehicle solution
Normalized name: compounding vehicle solution sugar free no. 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle solution
Study: 7855966
Drug: Sublingual liquid
Normalized name: B Complex with B-12 Sublingual Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual liquid preparation
Study: 7855966
Drug: Aqueous nasal
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous nasal spray
Study: 7855966
Drug: Controlled absorption
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled absorption 3 and 4 mg tablets
Study: 7855966
Drug: Home trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home trial use of controlled absorption tablets
Study: 7060486
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin administration via jet injector
Study: 7060486
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin administration via disposable syringe
Study: 30506427
Drug: Football (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Football (1 hour, twice weekly)
Study: 28700680
Drug: High frequency
Normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL SOLUTION [enMotion Foam High Frequency Use]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High frequency treatment groups
Study: 28700680
Drug: Low frequency
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low frequency treatment groups
Study: 25582611
Drug: lidocaine 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine 1.5 mg/kg
Study: 25582611
Drug: lidocaine 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine 0.5 mg/kg
Study: 21593661
Drug: Efavirenz (EFV)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz (EFV) 600 mg once daily
Study: 21890776
Drug: Nevirapine (NVP)
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine (NVP) 400 mg once daily (after 14 days of 200 mg)
Study: 19920270
Drug: Eszopiclone, 3
Normalized name: Eszopiclone, 3 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eszopiclone, 3 mg for the first 14 nights of CPAP
Study: 17353335
Drug: Optimal pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal pain medication (OPM)
Study: 14694167
Drug: Epoetin alpha
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin alpha to maintain hemoglobin between 120 and 130 g/L (group A)
Study: 14694167
Drug: Epoetin alpha
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin alpha to maintain hemoglobin between 90 and 100 g/L (group B)
Study: 10925934
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with epinephrine 5 microg x mL(‐1) (group E)
Study: 10925934
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine (group L)
Study: 8873934
Drug: Sidestream smoke
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sidestream smoke inhalation
Study: 6341271
Drug: Older girls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older girls (11-12 years) in treatment group
Study: 6341271
Drug: Younger boys
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Younger boys (10-11 years) in treatment group
Study: 29653812
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (2800 IU daily for 8 weeks)
Study: 25661470
Drug: Nurse-led heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led heart failure specific education session with three-month telephone follow-up in addition to standard medical treatment
Study: 12423432
Drug: Antibiotics/topical treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics/topical treatments
Study: 8910174
Drug: Metoclopramide 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 0.25 mg/kg IV
Study: 8910174
Drug: Ondansetron 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.15 mg/kg IV
Study: 1656521
Drug: Standard breakfast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard breakfast with 100 mg miglitol
Study: 1656521
Drug: Muesli with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muesli with 100 mg miglitol
Study: 6391134
Drug: Intravenous timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous timolol treatment
Study: 22875601
Drug: Secukinumab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab (150 mg single dose)
Study: 8992904
Drug: Rocuronium (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (0.6 mg/kg)
Study: 20236598
Drug: Rocuronium +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium + Neostigmine (0.04 mg/kg) and Atropine (0.02 mg/kg)
Study: 15065961
Drug: 16-week cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16-week cognitive-behavioral treatment for primary anxiety disorders
Study: 15065961
Drug: Positive responders
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Positive responders to anxiety treatment
Study: 11876837
Drug: rhGH (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (0.1 mg . kg(‐1) subcutaneously at 10 pm every evening for 14 days)
Study: 8538091
Drug: Bronchodilators only
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilators only (Control)
Study: 1286545
Drug: Shortened intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shortened intravenous glucose tolerance test (IVGTT)
Study: 1286545
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of glucose with model assessment (C.I.G.M.A.)
Study: 3891346
Drug: Nifedipine treatment
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine treatment (10 mg orally at onset, after 30 min, then every 6 h)
Study: 30705235
Drug: Multifactorial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifactorial intervention including a 2-hour workshop on best-practice regarding BZD prescription, monthly feedback on prescribing practices, and access to a support web page
Study: 22915730
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (control group, self-reported data)
Study: 22915730
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (control group, imputed self-reported outcomes)
Study: 20385632
Drug: HIE-erythropoietin group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIE-erythropoietin group (2500 IU/kg, subcutaneously, daily for 5 days)
Study: 10205211
Drug: Adrenaline injection
Normalized name: epinephrine Injection [Adrenalin]
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adrenaline injection
Study: 10205211
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (adrenaline injection and gold probe)
Study: 2692728
Drug: Mitoxantrone at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone at 14 mg/m2
Study: 2692728
Drug: Mitoxantrone at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone at 8 mg/m2
Study: 270863
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic treatment (previous series)
Study: 30874471
Drug: Bolus dose
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus dose epinephrine (BDE)
Study: 20216298
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (ERN) 500 mg/night titrated to 1500 mg/night for 12 weeks
Study: 18065594
Drug: L-Carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Carnitine (2 g levocarnitine once daily)
Study: 15855557
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg repaglinide
Study: 15855557
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg and 4 mg repaglinide
Study: 15855557
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg and 1 mg repaglinide
Study: 12393571
Drug: Screened patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screened patients for drug-dependent antibodies (DDABs)
Study: 10861613
Drug: Subdermal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subdermal injection of radiotracer on the tumor site plus a second injection of radiotracer (varied by group)
Study: 10861613
Drug: Different route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different route of injection (peritumoral or subdermal) on the tumor site
Study: 10999057
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg, 6 hourly for 7 days)
Study: 31553234
Drug: Olaparib tablets
Normalized name: Olaparib Tablets
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib tablets (300 mg twice daily) until disease progression, unacceptable toxicity, or another discontinuation criterion.
Study: 26980371
Drug: LY2495655 105
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2495655 105 mg
Study: 26980371
Drug: LY2495655 315
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2495655 315 mg
Study: 17336417
Drug: Candesartan cilexetil,
Normalized name: Candesartan Cilexetil, 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan cilexetil, 8 mg/d (N=24)
Study: 17336417
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (N=23)
Study: 12015902
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous administration of 12 million international units (MIU) of IL-2 followed by subcutaneous high-dose IL-2 (7.5 MIU, twice daily) for 5 days every 8 weeks
Study: 12015902
Drug: High-dose subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose subcutaneous IL-2 for 5 days every 8 weeks
Study: 12015902
Drug: Low-dose (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose (3 MIU, twice daily) subcutaneous IL-2 for 5 days every 4 weeks
Study: 9562580
Drug: Interferon gamma-1b
Normalized name: Interferon Gamma-1B
DrugBank: Interferon gamma-1b (DB00033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon gamma-1b (60 microg per square meter of body-surface area subcutaneously once weekly)
Study: 10955434
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oestradiol implants
Study: 7794850
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg oestradiol implants
Study: 3371393
Drug: Metoprolol CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR (controlled-release), 100 mg once daily
Study: 3371392
Drug: Conventional metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional metoprolol tablets, 100 mg once daily
Study: 3371393
Drug: Metoprolol CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR (controlled-release), 200 mg if needed
Study: 3371393
Drug: Conventional metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional metoprolol tablets, 200 mg if needed
Study: 3371393
Drug: All formulations
Normalized name: Novel Influenza-H1N1-09, all formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: All formulations of metoprolol
Study: 29042333
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen (1 g every 6 hours up to 18 hours postoperatively)
Study: 27493113
Drug: Combined treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment: esophagogastric devascularization with splenectomy followed by sclerotherapy (group B)
Study: 25271603
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of immunologically active gluten daily
Study: 18235409
Drug: First line
Normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL CLOTH [First Line Alcohol Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First line chemotherapy based on a combination of pemetrexed and cisplatin
Study: 18235409
Drug: Antiangiogenic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiangiogenic agents such as bevacizumab (Avastatin)
Study: 12518497
Drug: Negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control (20 teeth without Class I preparations)
Study: 19497245
Drug: Quetiapine (300-450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (300-450 mg/day) plus citalopram (60 mg/day)
Study: 19497245
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus citalopram (60 mg/day)
Study: 22171722
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of Straumann implants (SLActive®)
Study: 22171722
Drug: Early loading
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early loading of Straumann implants (SLActive®)
Study: 17267740
Drug: Ferric gluconate
Normalized name: Ferric Gluconate
DrugBank: Ferrous gluconate (DB14488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric gluconate 125 mg intravenously with eight consecutive hemodialysis sessions
Study: 12143473
Drug: Optiflow dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optiflow dual lumen catheters at 350 ml/min
Study: 12143473
Drug: Optiflow dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optiflow dual lumen catheters at 500 ml/min
Study: 12143473
Drug: PermCath dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PermCath dual lumen catheters at 300 ml/min
Study: 3294977
Drug: Azelastine 2
Normalized name: azelastine 2.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine 2 mg
Study: 7559264
Drug: Azelastine 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine 4 mg
Study: 3294977
Drug: Azelastine 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine 8 mg
Study: 3294977
Drug: Azelastine 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine 12 mg
Study: 3294977
Drug: Azelastine 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine 16 mg
Study: 30799375
Drug: Intracoronary darbepoetin‐α
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary darbepoetin‐α 300 μg
Study: 23372114
Drug: Darunavir/ritonavir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir monotherapy (DRV/r 800/100 mg once daily)
Study: 27279571
Drug: Darunavir/ritonavir with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors (NRTIs)
Study: 26460504
Drug: Darunavir/ritonavir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir monotherapy (DRV/r)
Study: 25988798
Drug: Standard-dose pentazocine/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose pentazocine/naloxone (50/0.5 mg)
Study: 25988798
Drug: Low-dose pentazocine/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose pentazocine/naloxone (25/0.25 mg)
Study: 23750517
Drug: NTC (No
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTC (No Treatment Control)
Study: 10052484
Drug: Prednisolone (125-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (125-150 mg i.v.)
Study: 7866820
Drug: OCM (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCM (omeprazole 20 mg once in the morning, clarithromycin 250 mg and metronidazole 400 mg twice daily)
Study: 7866820
Drug: OCT (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCT (omeprazole 20 mg once in the morning, clarithromycin 250 mg and tetracycline 500 mg twice daily)
Study: 31858823
Drug: Standard pelvic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pelvic floor muscle exercises and oscillating rod therapy
Study: 31858823
Drug: Standard pelvic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pelvic floor muscle exercises and relaxation therapy
Study: 22342864
Drug: Postinjury PUFAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postinjury PUFAs (850 mg/d)